Melotte Veerle, Yi Joo Mi, Lentjes Marjolein H F M, Smits Kim M, Van Neste Leander, Niessen Hanneke E C, Wouters Kim A D, Louwagie Joost, Schuebel Kornel E, Herman James G, Baylin Stephen B, van Criekinge Wim, Meijer Gerrit A, Ahuja Nita, van Engeland Manon
Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Dongnam Institute of Radiological and Medical Sciences (DIRAMS), Busan, South Korea.
Cancer Prev Res (Phila). 2015 Feb;8(2):157-64. doi: 10.1158/1940-6207.CAPR-14-0198. Epub 2014 Dec 23.
Identifying biomarkers in body fluids may improve the noninvasive detection of colorectal cancer. Previously, we identified N-Myc downstream-regulated gene 4 (NDRG4) and GATA binding protein 5 (GATA5) methylation as promising biomarkers for colorectal cancer in stool DNA. Here, we examined the utility of NDRG4, GATA5, and two additional markers [Forkhead box protein E1 (FOXE1) and spectrin repeat containing nuclear envelope 1 (SYNE1)] promoter methylation as biomarkers in plasma DNA. Quantitative methylation-specific PCR was performed on plasma DNA from 220 patients with colorectal cancer and 684 noncancer controls, divided in a training set and a test set. Receiver operating characteristic analysis was performed to measure the area under the curve of GATA5, NDRG4, SYNE1, and FOXE1 methylation. Functional assays were performed in SYNE1 and FOXE1 stably transfected cell lines. The sensitivity of NDRG4, GATA5, FOXE1, and SYNE1 methylation in all stages of colorectal cancer (154 cases, 444 controls) was 27% [95% confidence interval (CI), 20%-34%), 18% (95% CI, 12%-24%), 46% (95% CI, 38%-54%), and 47% (95% CI, 39%-55%), with a specificity of 95% (95% CI, 93%-97%), 99% (95% CI, 98%-100%), 93% (95% CI, 91%-95%), and 96% (95% CI, 94%-98%), respectively. Combining SYNE1 and FOXE1, increased the sensitivity to 56% (95% CI, 48%-64%), while the specificity decreased to 90% (95% CI, 87%-93%) in the training set and to 58% sensitivity (95% CI, 46%-70%) and 91% specificity (95% CI, 80%-100%) in a test set (66 cases, 240 controls). SYNE1 overexpression showed no major differences in cell proliferation, migration, and invasion compared with controls. Overexpression of FOXE1 significantly decreased the number of colonies in SW480 and HCT116 cell lines. Overall, our data suggest that SYNE1 and FOXE1 are promising markers for colorectal cancer detection.
识别体液中的生物标志物可能会改善结直肠癌的非侵入性检测。此前,我们确定N - Myc下游调控基因4(NDRG4)和GATA结合蛋白5(GATA5)甲基化是粪便DNA中结直肠癌很有前景的生物标志物。在此,我们检测了NDRG4、GATA5以及另外两个标志物[叉头框蛋白E1(FOXE1)和含核纤层蛋白重复序列的核膜蛋白1(SYNE1)]启动子甲基化作为血浆DNA中生物标志物的效用。对220例结直肠癌患者和684例非癌症对照者的血浆DNA进行了定量甲基化特异性PCR检测,分为训练集和测试集。进行了受试者操作特征分析以测量GATA5、NDRG4、SYNE1和FOXE1甲基化的曲线下面积。在稳定转染SYNE1和FOXE1的细胞系中进行了功能测定。在所有阶段的结直肠癌(154例,444例对照)中,NDRG4、GATA5、FOXE1和SYNE1甲基化的敏感性分别为27%[95%置信区间(CI),20% - 34%]、18%(95% CI,12% - 24%)、46%(95% CI,38% - 54%)和47%(95% CI,39% - 55%),特异性分别为95%(95% CI,93% - 97%)、99%(95% CI,98% - 100%)、93%(95% CI,91% - 95%)和96%(95% CI,94% - 98%)。在训练集中,将SYNE1和FOXE1联合使用,敏感性提高到56%(95% CI,48% - 64%),而特异性降至90%(95% CI,87% - 93%);在测试集(66例,240例对照)中,敏感性为58%(95% CI,46% - 70%),特异性为91%(95% CI,80% - 100%)。与对照相比,SYNE1过表达在细胞增殖、迁移和侵袭方面无明显差异。FOXE1过表达显著减少了SW480和HCT116细胞系中的集落数量。总体而言,我们的数据表明SYNE1和FOXE1是结直肠癌检测很有前景的标志物。